文献速递乳腺癌

弥合乳腺癌年龄差距:老年ER阳性早期乳腺癌省略手术的风险分层生存与生活质量分析

Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life.
PubMed 文献 · Eur J Cancer · 2020-11-18

这项英国多中心前瞻性观察队列研究纳入3416例≥70岁乳腺癌患者,其中2854例ER阳性,比较手术加内分泌治疗(S+ET)与单纯内分泌治疗(PET)。倾向匹配分析显示PET与较差总生存相关(HR=0.72,95%CI 0.53-0.98,P=0.04),但乳腺癌特异性生存无显著差异(HR=0.74,95%CI 0.40-1.37,P=0.34)。结论认为多数老年早期ER阳性患者手术肿瘤学更优,但对预期寿命不足5年的虚弱患者个体化选择PET可能安全。

要点

  • 多数老年早期ER阳性乳腺癌患者,手术加内分泌治疗肿瘤学优于单纯内分泌治疗。
  • 倾向匹配后PET仍与较差总生存相关,但乳腺癌特异性生存差异无统计学意义。
  • 对预期寿命不足5年的虚弱老年患者,个体化选择PET可能安全。

核心结论

  • 对于大多数老年早期ER阳性乳腺癌患者,手术在肿瘤学上优于单纯内分泌治疗。
  • 对于匹配队列中较不健康、更年长的女性,乳腺癌特异性生存差异至少随访4-5年消失,提示预期寿命不足5年者个体化选择PET可能安全。

研究设计与样本

  • 多中心、前瞻性、英国观察性队列研究,采用倾向匹配分析比较S+ET与PET。
  • 共纳入3416例女性(中位年龄77岁,范围69-102),来自56个乳腺单位;2854例(88%)为ER阳性乳腺癌,其中2354例接受S+ET,500例接受PET。
  • 倾向匹配基于年龄、健康状况和癌症分期,以调整分配偏倚;中位随访52个月。

主要发现

  • 未匹配分析中,PET组总生存较差(HR=0.27,95%CI 0.23-0.33,P<0.001)。
  • 未匹配分析中,PET组乳腺癌特异性生存也较差(HR=0.41,95%CI 0.29-0.58,P<0.001)。
  • 匹配分析中,PET仍与较差总生存相关(HR=0.72,95%CI 0.53-0.98,P=0.04),但乳腺癌特异性生存无显著差异(HR=0.74,95%CI 0.40-1.37,P=0.34),尽管4-5年时曲线开始有利于手术的细微分离。
  • 全球健康状况在某些时间点组间有差异,但调整基线差异后24个月内相似。

关键数值与推荐

  • 匹配队列中位年龄81岁,合并症和功能受损负担较高。
  • 对于预期寿命不足5年者(>90岁或>85岁伴合并症或虚弱),个体化决策PET与S+ET可能合适且安全。
  • Age Gap在线决策工具(https://agegap.shef.ac.uk/)可支持该决策过程。

临床怎么用

  • 对多数老年早期ER阳性乳腺癌患者,应优先考虑手术加内分泌治疗。
  • 对预期寿命不足5年的虚弱老年患者,可个体化讨论单纯内分泌治疗。
  • 可使用Age Gap在线决策工具辅助医患共同决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Age-related breast cancer treatment variance is widespread with many older women having primary endocrine therapy (PET), which may contribute to inferior survival and local control. This propensity-matched study determined if a subgroup of older women may safely be offered PET. METHODS: Multicentre, prospective, UK, observational cohort study with propensity-matched analysis to determine optimal allocation of surgery plus ET (S+ET) or PET in women aged ≥70 with breast cancer. Data on fitness, frailty, cancer stage, grade, biotype, treatment and quality of life were collected. Propensity-matching (based on age, health status and cancer stage) adjusted for allocation bias when comparing S+ET with PET. FINDINGS: A total of 3416 women (median age 77, range 69-102) were recruited from 56 breast units-2854 (88%) had ER+ breast cancer: 2354 had S+ET and 500 PET. Median follow-up was 52 months. Patients treated with PET were older and frailer than patients treated with S+ET. Unmatched overall survival was inferior in the PET group (hazard ratio, (HR) 0.27, 95% confidence interval (CI) 0.23-0.33, P < 0.001). Unmatched breast cancer-specific survival (BCSS) was also inferior in patients treated with PET (HR: 0.41, CI: 0.29-0.58, P < 0.001 for BCSS). In the matched analysis, PET was still associated with an inferior overall survival (HR = 0.72, 95% CI: 0.53-0.98, P = 0.04) but not BCSS (HR = 0.74, 95% CI: 0.40-1.37, P = 0.34) although at 4-5 years subtle divergence of the curves commenced in favor of surgery. Global health status diverged at certain time points between groups but over 24 months was similar when adjusted for baseline variance. INTERPRETATION: For the majority of older women with early ER+ breast cancer, surgery is oncologically superior to PET. In less fit, older women, with characteristics similar to the matched cohort of this study (median age 81 with higher comorbidity and functional impairment burdens, the BCSS survival differential disappears at least out to 4-5 year follow-up, suggesting that for those with less than 5-year predicted life-expectancy (>90 years or >85 with comorbidities or frailty) individualised decision making regarding PET versus S+ET may be appropriate and safe to offer. The Age Gap online decision tool may support this decision-making process (https://agegap.shef.ac.uk/). TRIAL REGISTRATION NUMBER: ISRCTN: 46099296.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wyld L, Reed MWR, Morgan J, et al. Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life. Eur J Cancer. 2020. PMID: 33220653. doi:10.1016/j.ejca.2020.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。